An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 and RedirecTT-1 trials.
Mary Caffrey
Advertisement
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles by Mary Caffrey
Anant Madabhushi, PhD, of Emory University, told attendees at the International Myeloma Society 21st Annual Meeting & Exposition how artificial intelligence's (AI) full potential in cancer care depends on its algorithms being validated by completed clinical trials.
A new consensus definition for high-risk myeloma patients and promising results from trials dedicated to their care may offer a "paradigm shift" in treatment, experts say at the International Myeloma Society 21st Annual Meeting & Exposition.
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, said panelists at the International Myeloma Society 21st Annual Meeting & Exposition.
Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affects Black patients.
A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.
The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.
Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set.
Based on an Avalere Health report, Community Oncology Alliance warns that IRA negotiations could slice down payments needed to administer cancer drugs.
Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
A review by authors from China examines evidence involving different treatment approaches.
Attendees of the first Institute for Value-Based Medicine® regional event will hear top experts from Boston-area institutions speak about treating non–small cell lung cancer, targeting HER2 in breast cancer, and identifying biomarkers in sarcomas.
The annual meeting of oncology stakeholders presented by The American Journal of Managed Care® takes place September 12-13, 2024.
Infectious diseases were the leading causes of death on the first Labor Day, just ahead of a major epidemiological shift that brought both vaccines to fight these deadly ailments but also the rise of cigarette smoking.
In this review, authors explain the supply chain issues of getting a life-saving treatment "vein to vein."
United Urology Group, with 4 practices in Maryland, Colorado, Arizona, and Tennessee, has agreed to be acquired by OneOncology, which last year was acquired by TPG and AmeriSourceBergen in a $2.1 billion transaction.
A review of the upcoming schedule of the Institute for Value-Based Medicine.
The immunotherapy combination was initially more costly but resulted in a lower cost of care over a 2-year period, investigators found.
A session on the final day of the 2024 Congress of the American Society of Preventive Cardiology explored the connections between autoimmune disease and cardiac events.
A debate on whether testing Lp(a) levels is actionable in primary prevention today offered lively discussion at the 2024 Congress of the American Society for Preventive Cardiology, being held in Salt Lake City, Utah.
A joint session with the Society for Cardiovascular Computed Tomography (SCCT) took place on the first day of the American Society for Preventive Cardiology 2024 Congress in Salt Lake City, Utah.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
2
Value-Based Care Interventions and Management of CKD Progression
3
Better Food, Better Health: Redefining Chronic Disease Care Through Nutrition
4
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
5
